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Abstract
Background: Foot-and-mouth disease virus (FMDV) causes an economically important and highly contagious
disease of cloven-hoofed animals. FMD control in endemic regions is implemented using chemically inactivated
whole-virus vaccines. Currently, efforts are directed to the development of safe and marked vaccines. We have
previously reported solid protection against FMDV conferred by branched structures (dendrimeric peptides)
harbouring virus-specific B and T-cell epitopes. In order to gain insights into the factors determining a protective
immune response against FMDV, in this report we sought to dissect the immunogenicity conferred by different
peptide-based immunogens. Thus, we have assessed the immune response and protection elicited in pigs by
linear peptides harbouring the same FMDV B-cell or B and T-cell epitopes (B and TB peptides, respectively).
Results: Pigs were twice immunized with either the B-cell epitope (site A) peptide or with TB, a peptide where the
B-cell epitope was in tandem with the T-cell epitope [3A (21-35)]. Both, B and TB peptides were able to induce
specific humoral (including neutralizing antibodies) and cellular immune responses against FMDV, but did not
afford full protection in pigs. The data obtained showed that the T-cell epitope used is capable to induce efficient
T-cell priming that contributes to improve the protection against FMDV. However, the IgA titres and IFNg release
elicited by these linear peptides were lower than those detected previously with the dendrimeric peptides.
Conclusions: We conclude that the incorporation of a FMDV specific T-cell epitope in the peptide formulation
allows a significant reduction in virus excretion and clinical score after challenge. However, the linear TB peptide
did not afford full protection in challenged pigs, as that previously reported using the dendrimeric construction
indicating that, besides the inclusion of an adecuate T-cell epitope in the formulation, an efficient presentation of
the B-cell epitope is crucial to elicit full protection by peptide vaccines.
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Background
Foot-and-mouth disease (FMD) is a highly infectious
disease of cloven-hoofed animals, and probably the most
important livestock disease in terms of economic impact
[1-3]. In many areas of the world (Africa, Asia and to
some extent, South America) FMD remains endemic
causing severe handicap for access to international
markets [4]. This endemic situation poses a constant
threat to countries that have a FMD-free status, which
has been increased over the last decade by the acceler-
ated trade and movements of people due to globaliza-
tion [5]. The risk of FMD introduction and spread into
countries or zones declared officially free has been con-
firmed by FMD outbreaks such as those in United King-
dom and the Netherlands (2001), China (2005), Russia,
Brazil and Argentina (2006) [6], and more recently in
Japan, Republic of Korea, China and Mongolia (2010)
(OIE information Database).
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ted by using chemically inactivated whole-virus vaccines.
The basic technology for vaccine production, which has
remained the same for decades, requires the growth of
large volumes of virulent FMDV, subsequent virus inac-
tivation, antigen concentration and purification [2,7].
This raises concerns on biosafety issues, as the risk of
virus release during vaccine production [2,8]. Additional
shortcomings of current FMD vaccines include: i) lack
of long-term protection, making multiple vaccinations
necessary; ii) Thermal instability, requiring an adequate
cold chain); iii) vaccinated animals exposed to infection
can become asymptomatic carriers, and iv) depending
upon the manufacturer, vaccines can contain traces of
non-structural proteins (NSP) making it difficult to dis-
tinguish between vaccinated and infected animals when
using currently approved assays [2,7,9]. These concerns
along with the severe trade restrictions applied in case
of any vaccination campaign, have led FMDV-free coun-
tries to adopt a non-vaccination policy that relies on
slaughtering infected and contact herds, and the strict
limitations on animal movements [10]. Therefore, much
effort has been invested in search of alternative, safe and
marked vaccines. Based on the virus capsid structure
and one main B-cell antigenic sites identified [11,12], a
number of strategies to develop new, alternative FMD
vaccines have been used. Among them, the use of syn-
thetic peptides offers clear advantages over conventional
vaccines addressing most of the above mentioned
caveats. The relatively simple production of clinical
grade, easily characterized vaccine peptides facilitates
quality control and regulatory approval, in addition to
allowing swift changes in design and thus rapid transla-
tion of new immunological concepts [13]. Even more
significant is the fact that peptide-based vaccines are by
nature free of any infectious component and thus inher-
ently fulfill the requirement of allowing differentiation
of vaccinated from infected animals (DIVA) [14].
Linear peptides spanning epitopes from VP1 of FMDV
have provided limited protection to viral challenge in
natural hosts [12,15]. The lack of T cell epitopes widely
recognized by T cells from individuals of domestic
populations of natural hosts, and capable of providing
adequate co-operation to immune B lymphocytes, has
been proposed as one of the limiting factors for the
development of efficient FMD peptide vaccines [16].
Recently we have reported solid protection against
FMDV challenge in pigs immunized with a dendrimeric
peptide construct [17] consisting of one copy of a T-cell
epitope [3A(21-35)] frequently recognized by outbred
pigs [18] that branches out into four copies of a B-cell
epitope (site A). This dendrimeric construction specifi-
cally induced high titers of FMDV-neutralizing antibo-
dies, the activation of T-cells, release of IFNg and a
potent anti-FMDV IgA responses (systemic and muco-
sal) [17].
To better understand the determinants of the protec-
tion conferred by this dendrimeric peptide, we have
assessed the immune response and protection elicited in
pigs by linear peptides containing the same B- and T-
cell FMDV epitopes displayed in the dendrimeric pep-
tide. Two groups of pigs were immunized with either
the B peptide or with TB, a peptide in which the B-epi-
tope was in tandem with the T-cell epitope (Table 1).
Both linear peptides were able to induce specific
humoral (including neutralizing antibodies) and cellular
immune response to FMDV, and conferred partial pro-
tection upon viral challenge, characterized by a delay on
the onset of signs which were less severe than those
observed in control non-immunized pigs. Interestingly
in the peptide-immunized animals, a post-challenge
reduction of FMDV excretion, more significant in TB
peptide-immunized pigs, was found. Compared with the
immune response elicited by the dendrimeric peptide
reported before [17], the more significant differences
f o u n df o rt h ep r e s e n ts e to fp e p t i d e sc o n c e r n e dI g A
titres and IFNg release, both displaying much lower
levels than those achieved with the dendrimeric peptide,
indicating a potential role of both effector mechanisms
in the protection against FMDV induced by such
peptide.
Results
Immunization with peptides B and TB affords partial
clinical protection to FMD challenge
Domestic Landrace x Large White pigs distributed in
three different groups, were vaccinated twice with B
peptide (group 1), TB peptide (group 2) or PBS and
challenged with type C FMDV (isolate C-S8c1). Animals
were examined daily monitoring rectal temperatures,
and a protection score (see details in Material and
Methods). Body temperatures above 39.5°C were
detected in pigs from group 3 (infection control group)
at 2 days post-challenge (Figure 1A). Two out of four
p i g sh a de l e v a t e dt e m p e r a t u r e sa b o v e4 1 ° Cf o rm o r e
than two days. In these animals, small vesicular lesions
were found on the snout, lips and tongue, as well as reg-
ular vesicles in the interdigital area or along coronary
band of more than two feet, around 3 days post-chal-
lenge. At four days post-challenge, three out of four pigs
from group 3 developed generalized clinical signs
(scored as 11,14 and 15) while the fourth showed clear
FMDV signs (score of 4), and the mean clinical score of
the group was 11 (Figure 1A).
None of the twelve pigs immunized with B or TB pep-
tides developed temperatures above 41°C during the 10
days post-challenge monitored (Figure 1A). In these pigs
a delay of two days in the detection of pyrexia (from
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mals was noticed. In addition, the presence of vesicular
lesions in more than two feet was found delayed, around
5 and 6 days post-challenge in groups 1 and 2, respec-
tively. Likewise, fifty per cent of the animals immunized
with peptide B (pigs B1, B2 and B5) and only one of the
six pigs immunized with TB peptide (pig TB6) showed
generalized FMD, which appeared significantly delayed
(7 days post-challenge), compared to those developed by
control pigs (group 3). The maximum clinical scores
(mean) registered along the post-challenge time course
were 9.8 (group 1), 6.8 (group 2) and 13,7 (group 3)
(Figure 1B). These differences were statistically signifi-
cant (P < 0.05) between group 2 (peptide TB) and
groups 1 and 3 (peptide B and control infection group,
respectively), suggesting that the presence of the T cell
epitope enhances the protection conferred.
Reduction of virus excretion after challenge in peptide-
vaccinated pigs
The time course of virus shedding in the challenged pigs
was analyzed by means of viral RNA detection in
Table 1 Synthetic peptides used in this study
Peptide FMDV protein (residues) Sequence
B VP1 [136-154] YTASARGDLAHLTTTHARH- amide
T 3A [21-35] AAIEFFEGMVHDSIK- amide
TB 3A [21-35]
VP1 [136-154]
AAIEFFEGMVHDSIKYTASARGDLAHLTTTHARH- amide
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Figure 1 A) Time course of clinical disease in challenged pigs immunized with peptide B (group 1), peptide TB (group2), and in non-
immunized pigs (group 3), after challenge with FMDV C-S8c1. The mean body temperature (°C) [right, rhombs] and the score of the clinical
signs (grey curve; calculated as indicated in Materials and Methods) are shown. B) Box plot showing the range of the maximum clinical scores
(see Materials and Methods) recorded for the individual animals from groups 1, 2 and 3 after challenge. Statistically significant differences were
found in the median values (line into the box) between groups 2 and 1 (* P = 0.026) and 2 and 3 (** P = 0.003).
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(Table 2). In group 3 (infection control animals) the
four pigs were positive for FMDV RNA in blood (vire-
mia), nasal and pharyngeal samples at 3 days post-infec-
tion. Blood and pharyngeal swabs from two control pigs
remained positive at 7 days post-infection. Virus RNA
could be detected in nasal swabs from the four animals
for the entire period of examination, except for pig C4
at 10 days post-infection. On the other hand, the total
number of samples positive for viral RNA in groups 1
and 2 (peptide-immunized pigs) was clearly lower (18
and 4 out of 42 samples tested, respectively) compared
to those detected in the group 3 (23 out of 36 samples
tested). At 7 days post-infection the viral RNA detection
pattern in both immunized groups was clearly different;
while in group 1 (B peptide-immunized animals) swab
samples from three pigs were positive, in group 2 (TB
peptide-immunized animals) only one positive sample
was detected. At 10 days post-infection all the samples
tested from both groups (1 and 2) were FMDV RNA
negative.
To further determine the relative level of FMDV repli-
cation in the different pig groups, at 10 days post-infec-
tion during the necropsy, several tissues were collected
and tested for FMDV RNA detection (Table 3). Similar
to viral RNA detection in blood and swabs, the number
of RNA positive tissues was lower in group 2 compared
to groups 1 and 3, excluding lymph nodes that were
positive in all the pigs. Overall, as found with the sever-
ity of the clinical signs, a lower extent of FMDV replica-
tion was observed in challenged animals immunized
with peptide TB.
Peptides B and TB elicit neutralizing and specific IgG1,
IgG2 and IgA antibodies
Upon revaccination, all the 12 immunized pigs (groups
1 and 2) showed a rise in serum neutralizing antibody
titres at day 39 (18 days post-boost), which increased
significantly (P < 0.05) again at day 49 (10 days after
challenge) (Table 4). No significant VN-titre differences
were detected between groups 1 (B-immunized pigs)
and 2 (TB-immunized pigs) at day 39, and after FMDV
challenge at day 49. In these animals, no rise of VN-
titres was detected after a single peptide dose (day 21),
except in two animals: B1 (group 1) and TB5 (group 2)
(Table 4).
All immunized pigs showed detectable serum levels of
IgG1, IgG2 and IgA antibodies against FMDV on day 39
(18 days post-boost) (Table 4), but not after the first
immunization (data not shown). Since the isotype-speci-
fic assays used were not absolute quantitative (did not
include known isotype standars), only comparisons
Table 2 Detection of FMDV RNA in blood and respiratory tract samples (nasal and pharyngeal swabs) from challenged
pigs
Day post-challenge
03 7 1 0
Group Inoculum Pig B
a N
b P
c BN PBNPBNP
1 B peptide B1 - na
d na + na na - na na - na na
B2 - na na + na na + na na - na na
B3 - -
e -- +
f +-- --- -
B4 - - - - - + - + + - - -
B5 - - - + - + + + + - - -
B 6 - - -+++-++-- -
2 TB peptide TB1 - na na + na na - na na - na na
TB2 - na na - na na - na na - na na
TB3 - - - + - + - - - - - -
T B 4- - ---+------
T B 5- - --- -------
T B 6- - --- ---+---
3 PBS C1 - -- ++++++-+ -
C2 - -- +++-+ - -+ -
C3 - -- +++-+ - -+ -
C4 - -- ++++++- --
a Blood
b Nasal swabs
c Pharyngeal swabs
d sample not available
e RNA not detected
f RNA detected
Cubillos et al. Virology Journal 2012, 9:66
http://www.virologyj.com/content/9/1/66
Page 4 of 11Table 3 Detection of FMDV RNA in tissue samples collected post-mortem (10 days post-challenge)
Group Inoculum Pig Detection of FMDV RNA
Heart Lung Spleen Liver Kidney Tonsil Lymph node
1 B peptide B1 --+- - - +
B2 +- ++ - + +
B3 -- - - - - +
B4 -- - - - + +
B5 +- ++ - + +
B6 --+- - + +
2 TB peptide TB1 - - - - - - +
TB2 -- - - - - +
TB3 +- - - - - +
TB4 -- - - - + +
TB5 -- -+- - +
TB6 --+- - + +
3 PBS C1 +- +++ + +
C2 +- + - + + +
C3 --+-++ +
C4 --++- + +
Table 4 Serum neutralising antibodies and isotype-specific responses (IgG1, IgG2 and IgA) in serum samples from
challenged pigs
VNT IgG1 IgG2 IgA
Group Inoculum Pig 39
a 49
b 39
a 49
b 39 49 39 49
1 B peptide B1 2.5 2.8 5,0 4,1 4,4 4,3 4,1 3,7
B2 2,2 2.5 2,7 3,0 2,5 2,7 3,0 2,8
B3 2.5 3.4 3,4 2,8 3,1 2,7 2,8 3,0
B4 2.2 3.4 2,7 2,9 2,4 3,0 2,4 2,8
B5 1.9 3,7 2,3 3,6 2,2 3,8 2,7 3,0
B6 2,2 3,1 2,5 3,1 2,1 3,0 2,2 3,0
mean
c 2,2 3,1 3,0 3,2 2,7 3,2 2,8 3,0
sd
d ±0 . 2 ±0 . 4 ±1 ±1 ±1 ±1 ±0 , 7 ±0 , 3
2 TB peptide TB1 2,5 2,8 2,0 2,1 2,0 2,0 2,3 2,5
TB2 2,2 2,8 2,8 2,8 2,6 2,6 2,7 2,8
TB3 1.9 2,5 2,3 2,8 2,2 2,7 2,1 2,7
TB4 1.9 3.1 2,0 2,8 2,4 3,2 2,5 2,7
TB5 3.1 3,4 2,6 3,1 2,6 3,3 2,6 2,9
TB6 2.5 2.8 3,2 3,6 2,9 3,4 2,9 3,0
mean 2,3 2,9 2,4 2,8 2,4 2,8 2,5 2,8
sd ± 0,4 ± 0,3 ± 0,5 ± 0,5 ± 0,3 ± 0,5 ± 0,3 ± 0,2
3 PBS C1 - 3.1 - 3 - 2,9 - 3,5
C2 - 2,8 - 2,5 - 2,2 - 2,7
C3 - 3.1 - 2,6 - 2,3 - 2,9
C4 - 2,8 - 2,0 - 2,4 - 2,7
mean 2,9 2,5 2,4 2,9
sd ± 0,1 ± 0,4 ± 0,3 ± 0,4
a Sample collected at day 39 (18 days after peptide boost).
b Sample collected at day 49 (10 days post-challenge).
c Mean isotype titres.
d Standard deviation.
- Sample not available.
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sible. No significant differences in IgG1, IgG2 and IgA
titres were found between groups 1 and 2 at days 39
and 49, nor compared to the isotypes detected in group
3 (infection control pigs) at day 49.
Therefore, these results suggest that the presence of
the T-cell epitope does not modify the magnitude or
isotype switching of the antibody response. However,
differences in antibody affinities induced by peptides B
and TB, which might enhance the protection conferred,
cannot be ruled out.
Peptides B and TB induce FMDV-specific T cell responses
Induction of FMDV-specific T-cells was analyzed by lym-
phoproliferation assays with PBMCs collected from pep-
tide-immunized pigs at days 0, 21 and 39, and stimulated
in vitro with peptides (B or TB) or virus. No stimulation
in response to peptides or virus was observed with
PBMCs obtained from the animals prior to immunization
(day 0). After the first immunization, day 21, specific
responses to peptides started to be detectable with SI (<
4) and such responses were not observed for whole-virus
antigen (data not shown). Higher specific responses (SI >
6) against peptides B or TB were found for lymphocytes
from all peptide-immunized pigs at day 39 (18 days post-
boost) (Figure 2). The magnitude of these responses
showed animal-to-animal variation, but a consistent
trend was noticed: responses against peptide and virus
were higher in TB-immunized pigs than in B-immunized
pigs. In all cases, maximal responses were induced with
20 μg/ml of peptides B or TB.
The lymphoproliferative response against whole-virus
antigen significantly differed between groups 1 and 2.
All animals immunized with peptide TB (group 2)
responded to virus with SI > 2.5. However, PBMCs from
only two of the six animals immunized with peptide B
(group 1) significantly proliferated against virus stimula-
tion (SI > 2) (Figure 2). In addition, a correlation was
observed between response against peptide and whole-
virus antigen in group 2 but not in group 1.
Production of IFN-g and IL10 was analyzed in super-
natants of PBMCs from immunized pigs at day 39, in
response to in vitro stimulation with peptides B or TB,
as well as in supernatants from mock-stimulated cul-
tures. Low levels of IFNg production (8-10 pg/ml), were
detected in supernatants of PBMCs from pigs TB4 and
TB5 (group 2), in response to in vitro stimulation with
peptide TB but not in mock-stimulated cultures (data
not shown). Production of this Th1 cytokine was not
detected in any of the B peptide-immunized pigs (group
1). Likewise, no IL10 was detected in pigs from either of
the groups (data not shown).
These results support the theory that the presence of
the T-cell epitope favors the priming of specific T-cells
in the immunized animals, which could be recalled effi-
ciently upon FMDV stimulation.
Discussion
Vaccines based on synthetic peptides offer several
advantages when compared with conventional vaccines
based on attenuated or inactivated microorganisms, par-
ticularly regarding safety, thermal stability and ease of
production. Despite the potential advantages of this
approach, the development of successful peptide vac-
cines has been limited mainly by difficulties associated
with in vivo stability, poor immunogenicity of linear
peptides, and by the MHC polymorphism of the host
species [19,20]. However, recent advances on the
requirements for induction and maintenance of immune
responses, as well as on the pharmacokinetics of pep-
tides, have provided new strategies to enhance both,
peptide immunogenicity and stability, which are leading
to the return of peptide based technologies to the fore-
front of vaccine design [21,22].
The use of one of such approach, the multimerization
of peptides by dendrimeric constructs, has recently
allowed us to report solid protection against FMDV
challenge [17]. The peptide dendrimer used B4T, con-
tained four copies of an immunodominant B-cell epi-
tope, named site-A, branched out a selected Th epitope
of FMDV broadly recognized by T-cells from outbred
pigs [18]. This dendrimeric construction specifically
induced high titers of FMDV-neutralizing antibodies,
activated T-cells, release of IFNg and a potent anti-
FMDV IgA response [17]. However, whether the immu-
nogenicity and protection elicited by this dendrimeric
peptide was due to incorporation of a relevant T-cell
epitope and/or to the presence of a dendrimeric struc-
ture containing repeated B-cell epitopes remained to be
addressed.
As part of the understanding of the determinants of
the protection afforded by peptide B4T, we have ana-
lyzed the immune response and the protection conferred
in pigs by linear peptides containing the B- and the T-
cell epitopes displayed in the dendrimeric peptide.
As shown in Figure 1, immunization of pigs with lin-
ear peptides (B or TB) was not able to confer full pro-
tection as that reached using peptide B4T. However,
significant differences on the maximum clinical scores
were observed between the two groups of immunized
animals (Figure 1B), being the values lower for animals
immunized with peptide TB (group 2) (Figure 1B).
These results correlate with the significant reduction of
FMDV RNA detection after viral challenge in blood,
nasal and pharingeal swabs in animals immunized with
peptide TB (Table 2). Therefore, vaccination with a lin-
ear peptide displaying a specific T-cell epitope, can
reduce virus excretion in pigs, which might contribute
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the pigs are not fully protected. Similar improved con-
trol of FMDV replication in mice has been achieved by
DNA vaccines encoding one B and two T cell epitopes
[23]. However, to reach the same protection results in
pigs, the B and T epitopes encoded by the DNA vaccine
requires to be tagerted to Class-II swine leukocyte anti-
gens [24].
The protection against FMDV conferred by conven-
tional whole virus vaccine broadly correlates with the
virus neutralizing antibody levels present in serum in
cattle and, to a lesser extent, in pigs [7,25,26]. Our
results show a lack of correlation between neutralizing
antibody levels and protection, as the levels of virus
neutralizing antibodies induced by both peptides B and
TB were similar (around 2 log10), and even similar to
those previously reported for peptide B4T [17]. A similar
lack of correlation has been reported in animals immu-
nized with vaccines different from those based on inacti-
vated FMDV [27].
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Figure 2 Proliferative response against peptides (20 μg/ml per well) and virus (5·10
5 pfu/ml) of PBMCs obtained at day 39 from
peptide-immunized pigs (group 1 and 2). Results are expressed as SI and each bar represents the mean of triplicate cultures. The background
cpm values (obtained with lymphocytes incubated with medium alone or mock-infected cells) were always ≤ 2300 cpm.
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mechanisms [28]. Thus, the lower protective effect of
the antibodies induced by linear peptides (B or TB)
could be due to differences in either the mechanisms of
neutralization they exert (i.e. direct neutralization of
receptor binding, Fc-g-receptor-dependent viral clear-
ance, complement-mediated lysis, antibody-dependent
cytotoxicity) or to affinity differences. To assess other
humoral factors potentially contributing to limited pro-
tection conferred by the linear peptides, the spectrum of
immunoglobulin subclasses induced by peptides T and
TB was analysed. Our results show that linear peptides
were able to induce significant titres of specific IgG1,
IgG2 and IgA at day 39 (18 days after boost). The mag-
nitude of these isotype responses was similar after B and
TB immunization, suggesting that the inclusion of the
T-cell epitope has no influence on the antibody isotype
switch. However, the IgA titres induced by both linear
peptides are between 1 and 2 orders of magnitude lower
than those reported previously for dendrimer vaccina-
tion [17]. Therefore, IgA induction seems to be depen-
dent on the branched structure and not only on the
presence of the T-cell epitope. Induction of IgA
responses has been recently correlated with complete
protection against FMDV challenge of pigs immunized
with a highly concentrated, inactivated vaccine [29]. All
together, this result indicates that the lack of full protec-
tion conferred by linear peptides is, a large extend due
to the inefficient induction of specific IgA.
The highly repetitive array of epitopes on viral sur-
faces allows efficient crosslinking of antigen-specific
immunoglobulins on B cells, constituting a strong acti-
vation signal that may even overcome B cell tolerance
[30]. In contrast to linear monomeric peptides, dendri-
mers display a repetitive configuration, which could
allow direct activation of B cells, leading to a rapid B
cell proliferation and production of antibodies. Likewise
the triggered B cells are able to activate T helper cells,
leading to cytokine secretion that can result in a suitable
environment for generation of B cell memory. Therefore
the activation of these early mechanisms by dendrimeric
peptides, but not by monomeric peptides, can be rele-
vant for the induction of protective immune responses
against FMDV. Further studies are required to test this
hypothesis, by analyzing the interaction between dendri-
meric versus monomeric peptides with different antigen
presenting cells essential in the early specific responses
(B cells, Dendritic cells, gδ T lymphocytes, etc.).
Besides the direct neutralization of viral infectivity,
other mechanisms of viral clearance may operate in
vivo, as T-cell activation and the balance of cytokines
they release. Immunization with peptides B or TB eli-
cited T cells that consistently proliferate when stimu-
lated with the peptides (Figure 2). However, the
lymphoproliferative response to FMDV was significantly
higher for TB-immunized pigs( F i g u r e2 ) .T h e s er e s u l t s
show that the inclusion of the specific T-cell epitope in
the peptide formulation allows priming of T cells that
can recognize more efficiently the viral epitopes pre-
sented in the context of a subsequent virus encounter.
Upon in vitro stimulation, primed T cells from two
pigs immunized with the linear peptide TB released
IFNg, which was not detected in any of the animals
immunized with peptide B. These results indicate that
the inclusion of the FMDV T-cell epitope enhances the
IFNg release. However, since the IFNg release is higher
after dendrimer vaccination [17], we can assume that
optimal IFNg production requires the inclusion of an
efficient T-cell epitope, as well as a suitable configura-
tion. IFNg is a major activator of macrophages, enhan-
cing their antimicrobial activity and their capacity for
processing and presenting antigens to T lymphocytes
[31]. It has been reported that IFNg stimulates MHC
expression in antigen-presenting cells and that efficiently
inhibits FMDV replication [32]. Therefore, these results
suggest that the better clinical protection conferred by
the TB peptide compared to B peptide, is mostly due to
the induction of a more efficient lymphoproliferative
response and IFNg release.
Taken together, our results show that the incorpora-
tion of a specific T-cell epitope in the peptide formula-
tion seems to be necessary but not sufficient to enhance
the protective cellular response to the protective levels
achieved by a dendrimeric peptide. Thus, even though
further work is required to understand the details of
mechanisms leading to the solid protection conferred by
dendrimeric peptides, our results suggest that branched
configuration along with the inclusion of a T-cell epi-
tope are essential to induce protective immune
responses characterized mainly by high specific IgA
responses and production of IFNg.
Conclusions
From the results obtained in this study, we conclude that
the incorporation of a FMDV specific T-cell epitope in
the peptide formulation allows a significant reduction in
virus excretion and clinical score after challenge. How-
ever, the linear TB peptide did not afford full protection
in challenged pigs, as that previously reported using the
dendrimeric construction indicating that, besides the
inclusion of an adequate T-cell epitope in the formula-
tion, an efficient presentation of the B-cell epitope is cru-
cial to elicit full protection by peptide vaccines.
Methods
Synthetic peptides
Peptides in Table 1 were prepared by automated synth-
esis performed in an Applied Biosystems model 433
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mmol FastMoc protocols on Fmoc-Rink-amide-MBHA
resin, with 10-fold excess of Fmoc-protected-L-amino
acids and HBTU coupling chemistry. Protected peptide
resins were N-deblocked prior to full deprotection and
cleavage with trifluoroacetic acid-water-triisopropylsilane
(95:2.5:2.5 v/v, 90 min, rt). Peptides were precipitated by
addition of chilled diethyl ether, taken up in aqueous
HOAc (10% v/v) and lyophilized. Analytical reversed-
phase HPLC was performed on a C18 column (4.6 × 50
mm, 3 μm ) ,s o l v e n tA0 . 0 4 5 %T F Ai nH 2O, solvent B
0.036% in ACN, flow rate 1 ml/min, UV detection at
220 nm. Preparative HPLC was performed on C18 col-
umn (21.2 × 250 mm, 10 μm), solvent A 0.045% TFA in
H2O, solvent B 0.036% in ACN, flow rate 25 ml/min.
Linear gradients of solvent B into A were used for elu-
tion. Fractions of adequate purity (HPLC > 95%) and
with the expected mass (MALDI-TOF, Voyager DE-
STR, Applied Biosystems, Foster City, CA, a-hydroxy-
cinnamic acid matrix; spectra obtained in the reflector
mode) were combined and lyophilized.
Virus
A virus stock derived from type C FMDV isolate C-S8c1
(18) by two passages in BHK-21 cells, which maintained
the consensus sequences at the capsid protein region
[33], was used in this study.
Immunization and infection of pigs
Two vaccine-challenge experiments were carried out
involving 16 domestic Landrace x Large White 8-weeks-
old pigs, distributed in three different groups. Two of
these groups, consisting of 6 pigs each, were vaccinated
twice by intramuscular injection with 1 ml of 0.35 μMB
peptide (group 1) or TB peptide (group 2), emulsified
with complete Freund’s adjuvant at day 0, and with
incomplete Freund’s adjuvant at day 21. The third group
of 4 pigs (group 3) was used as infection-control group.
Pigs were housed in a high-containment unit, each
group in a separate room. Eighteen days after boost, ani-
mals were challenged intradermally in the left rear foot
with 10
4 PFU of FMDV C-S8c1. Animals were examined
daily monitoring rectal temperatures, and a protection
score based on the time of appearance and the number
and severity of lesions was determined. Total protection
was defined as complete absence of lesions (score 0)
and score values below 8 were considered as partial pro-
tection Clinical score was calculated as follows [34]: i)
an elevated body temperature of 40°C (score of 1), >
40.5 (score of 2), or > 41 (score 3); ii) reduced appetite
(1 point) or no food intake and food left over from the
day before (2 points); iii) lameness (1 point) or reluc-
tance to stand (2 points); iv) presence of heat and pain
after palpation of the coronary bands (1 point) or not
standing on the affected foot (2 points); v) vesicles on
the feet, dependent on the number of feet affected, with
a maximum of 4 points; and vi) visible mouth lesions on
the tongue (1 points), gums or lips (1 point) or snout (1
point), with a maximum of 3 points.
All experiments with live animals were performed
under the guidelines of the European Union (EU direc-
tive 86/609/EEC) and were approved by the site ethical
review committee.
Virus neutralization test (VNT)
Virus-neutralizing activity was determined in sera using
a standard micro-neutralization test performed in 96-
well plates by incubating serial two-fold dilutions of
each serum with 100 TCID50 (50% Tissue Culture
Infective Dose) of FMDV C-S8c1 for 1 h at 37°C.
Remaining viral activity was determined in 96-well
plates containing fresh monolayers of BHK-21 cells.
End-point titres were calculated as the reciprocal of the
final serum dilution that neutralized 100 TCID50 of
FMDV C-S8c1 in 50% of the wells [35].
Detection of isotype-specific FMDV antibodies
FMDV-specific IgG1, IgG2 and IgA in sera were mea-
sured using monoclonal antibodies specific for these iso-
types supplied by Serotec, and 100 μLo fd u p l i c a t e
threefold dilution series of each serum (starting at 1/50),
as described [17]. In these assays the point on the titra-
tion curve corresponding to A492 of 1.0 invariably fell
on the linear part of the curve. Antibody titers were
therefore expressed as the reciprocal of the last dilution
calculated by interpolation to give an absorbance of 1.0
OD unit above background.
Lymphoproliferation assays
Proliferation assays of swine lymphocytes were per-
formed as described [17,18]. Blood was collected in 5
μM EDTA and used immediately for the preparation of
peripheral blood mononuclear cells (PBMCs). Assays
were performed in 96-well round-bottomed microtiter
plates (Nunc). Briefly, 2.5 × 10
5 PBMCs per well were
cultured in triplicate, in a final volume of 200 μL, in
complete RPMI 10% (v/v) FCS, 50 μM 2-mercapto-etha-
nol, in the presence of various concentrations of: i)
FMDV, ranging from 3 × 10
5 to 2 × 10
3 PFU, ii) syn-
thetic peptides, ranging from 50 μg/mL to 10 μg/mL.
Cultures with medium alone or with mock-infected cells
were included as control for each blood sample. Cells
were incubated at 37°C in 5% CO2 for 4 days. Following
incubation, each well was pulsed with 0.5 μCi of methyl-
[3H] thymidine for 18 h. Cells were collected using a
cell harvester and the incorporation of radioactivity into
the DNA was measured by liquid scintillation in a
Microbeta counter (Pharmacia). Results were expressed
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mean cpm of stimulated cultures/mean cpm of cultures
grown in the presence of medium alone (peptide) or
mock-infected cells (virus).
Cytokine detection
PBMC supernatants were cultured with 20 μg/ml of B
or TB peptides for 48 h and analyzed for cytokine
expression using interleukin-10 (IL-10) CytoSets (Bio-
source) and gamma interferon (IFNg) ELISA (Pierce,
Endogen) kits. In each assay the corresponding recombi-
nant porcine cytokine was diluted over the detection
range recommended by the manufacturer to generate a
standard curve from which sample concentrations (in
pg/ml) were calculated.
RT-PCR
FMDV RNA in blood and in nasal and pharyngeal
swabs, as well as in different biological samples collected
at sacrifice day, was amplified by RT-PCR and detected
as described [36]. We used the Primers A (5’-
ACACGGCGTTCACCCA(A/T)CGC-3’)a n dB( 5 ’-
GACAAAGGTTTTGTTCTTGGTC-3’)d e s i g n e dt o
bracket a 290-bp region in the FMDV 3D polymerase
gene.
Statistical analysis
The statistical significance of differences in the clinical
score values and antibody isotype titers between groups
were calculated by the Mann-Whitney rank sum test.
The Student’s t test was used for VNT comparisons
between groups 1 (B-immunized pigs) and 2 (TB-immu-
nized pigs). Statistical analyses were performed using
the SigmaStat software.
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